Yahoo Web Search

Search results

  1. James Patrick Allison (born August 7, 1948) is an American immunologist and Nobel laureate who holds the position of professor and chair of immunology and executive director of immunotherapy platform at the MD Anderson Cancer Center in Houston, Texas.

  2. Oct 22, 2018 · Jim Allison is an iconoclastic scientist who toiled in obscurity for years. Then he helped crack a mystery that may save millions of lives: Why doesn’t the immune system attack cancer?...

  3. Dr. James Allison is Regental Professor and Chair of the Department of Immunology, the Olga Keith Wiess Distinguished University Chair for Cancer Research, Director of the Parker Institute for Cancer Research, Executive Director of the Immunotherapy Platform, and Director of the James P. Allison Institute at MD Anderson Cancer Center.

    • Jim Allison1
    • Jim Allison2
    • Jim Allison3
    • Jim Allison4
    • Jim Allison5
  4. James P. Allison. The Nobel Prize in Physiology or Medicine 2018. Born: 7 August 1948, Alice, TX, USA. Affiliation at the time of the award: Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; University of Texas MD Anderson Cancer Center, Houston, TX, USA.

  5. Jim Allison, Ph.D., is a MD Anderson Cancer Center scientist who discovered how to unleash the immune system to fight cancer. He received the 2018 Nobel Prize in Physiology or Medicine for his groundbreaking research on immune checkpoint inhibitors.

  6. Nov 18, 2019 · Jim Allison, Ph.D., is the chair of Immunology and executive director of the Immunotherapy platform at MD Anderson. He developed ipilimumab, a checkpoint inhibitor that has been approved to treat several cancers, and received the 2018 Nobel Prize in Physiology or Medicine for his work.

  7. Jim Allison is a renowned immunologist and cancer researcher who pioneered immune checkpoint blockade as a cancer treatment. He is a professor and chair of Immunology at MD Anderson, and has received many awards and honors, including the Nobel Prize in Medicine in 2018.